title: Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.
authors.affiliation: Division of Gastroenterology Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Wright
authors.affiliation: Division of Gastroenterology Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Fontana
authors.affiliation: Division of Gastroenterology Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
authors.forename: Ryan W
authors.initials: RW
authors.lastname: Stidham
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; C543529:vedolizumab